Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.

被引：2
|
作者：
Harrington, Kevin Joseph
Kong, Anthony
Mach, Nicolas
Chesney, Jason Alan
Castelo, Beatriz
Rischin, Danny
Cohen, Ezra E. W.
Radcliffe, Hoi-Shen
Gumuscu, Burak
Snyder, Wendy
Siu, Lillian L.
机构：
[1] Royal Marsden Inst Canc Res NIHR Biomed Res Ctr, London, England
[2] Univ Birmingham, Inst Canc & Genom Sci, Birmingham, W Midlands, England
[3] Univ Hosp Geneva, Dept Oncol, Geneva, Switzerland
[4] Univ Louisville, Brown Canc Ctr, Louisville, KY 40292 USA
[5] La Paz Univ Hosp, Dept Med Oncol, Madrid, Spain
[6] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[7] Univ Calif San Diego, San Diego, CA 92103 USA
[8] Amgen Inc, Uxbridge, Middx, England
[9] Merck & Co Inc, Kenilworth, NJ USA
[10] Amgen Inc, Thousand Oaks, CA 91320 USA
[11] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.6036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6036
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study
    Adkins, Douglas
    Mehan, Paul
    Ley, Jessica
    Siegel, Marilyn J.
    Siegel, Barry A.
    Dehdashti, Farrokh
    Jiang, Xuntian
    Salama, Noha N.
    Trinkaus, Kathryn
    Oppelt, Peter
    LANCET ONCOLOGY, 2018, 19 (08): : 1082 - 1093
  • [22] First-Line Pembrolizumab With or Without Lenvatinib in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 3 LEAP-010 Study
    Harrington, Kevin
    Siu, Lillian L.
    Burtness, Barbara
    Cohen, Ezra
    Licitra, Lisa
    Rischin, Danny
    Zhu, Ying
    Okpara, Chinyere E.
    Pinheiro, Cecilia
    Swaby, Ramona F.
    Machiels, Jean-Pascal
    Tahara, Makoto
    ORAL ONCOLOGY, 2021, 118
  • [23] Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Siu, Lillian L.
    Burtness, Barbara
    Cohen, Ezra E. W.
    Harrington, Kevin Joseph
    Licitra, Lisa F.
    Rischin, Danny
    Zhu, Ying
    Lee, Chooi Peng
    Pinheiro, Cecilia
    Swaby, Ramona F.
    Machiels, Jean-Pascal H.
    Tahara, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Systemic treatment for pre-treated recurrent/metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (HNSCC): a comprehensive review of randomized phase III data
    Roets, Evelyne
    Govarts, Anouk
    van Gogh, Evelien
    Tukanova, Karina
    Specenier, Pol
    ACTA CLINICA BELGICA, 2017, 72 : 14 - 14
  • [25] Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.
    Fayette, Jerome
    Clatot, Florian
    Brana, Irene
    Saada, Esma
    van Herpen, Carla M. L. -
    Mazard, Thibault
    Perez, Cesar Augusto
    Tabernero, Josep
    Le Tourneau, Christophe
    Hollebecque, Antoine
    Arrula, Virginia Arrazubi
    Fontana, Elisa
    Kato, Shumei
    Sacco, Assuntina G.
    Harandi, Amir
    De Boer, J. P.
    Hellyer, Jessica
    Pennella, Eduardo
    Joe, Andrew K.
    Daste, Amaury
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Bauman, Julie E.
    Roe, Denise
    Saba, Nabil F.
    Bauman, Jessica Ruth
    Kaczmar, John M.
    Burtness, Barbara
    Muzaffar, Jameel
    Julian, Ricklie Ann
    Wang, Steven
    Bearelly, Shethal
    Baker, Audrey
    Steuer, Conor Ernst
    Bhatia, Aarti K.
    Giri, Anshu
    Caulin, Carlos
    Stabile, Laura P.
    Centuori, Sara
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC)
    Saba, N.
    Youssoufian, H.
    Cohen, E.
    Singh, J.
    Makris, L.
    Perdomini, M.
    MacIntyre, S.
    Denker, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S592 - S592
  • [28] Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
    Licitra, L.
    Tahara, M.
    Harrington, K.
    Hurtado de Mendoza, M. Olivera
    Guo, Y.
    Aksoy, S.
    Fang, M.
    Zurawski, B.
    Csoszi, T.
    Klochikhin, M.
    de Oliveira, T. B.
    Takahashi, S.
    Yang, M. H.
    Swiecicki, P. L.
    O'Hara, K.
    Shen, J.
    Wang, A.
    Gumuscu, B.
    Benjamin, K.
    Haddad, R. I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E2 - E3
  • [29] Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    Cohen, E. E. W.
    Algazi, A.
    Laux, D.
    Wong, D. J.
    Amin, A.
    Nabell, L.
    Chisamore, M.
    Gamelin, E.
    Janssen, R.
    Bishnoi, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 375 - 375
  • [30] Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 treatment naive patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    Cohen, Ezra
    Bishnoi, Sarwan
    Laux, Douglas E.
    Wong, Deborah
    Amin, Asim
    Nabell, Lisle
    Schmidt, Emmett V.
    Xing, Biao
    Leung, Abraham C.
    Janssen, Robert
    CANCER RESEARCH, 2018, 78 (13)
12345